SIM
CARM

Spark Investment Management’s Carisma Therapeutics CARM Stock Holding History

Spark Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,730
Closed -$148K – 723
2017
Q2 		$148K Buy
+4,730
New +$158K 0.01% 691
2017
Q1 		– Sell
-7,025
Closed -$268K – 822
2016
Q4 		$268K Buy
+7,025
New +$309K 0.02% 592

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $9.05B AUM 13.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Spark Investment Management's CARM Position: Q3 2017 in Review

Spark Investment Management sold out of Carisma Therapeutics (CARM) in Q3 2017, closing a stake of 4,730 shares — an estimated $148K sold.

Spark Investment Management first reported a position in CARM in Q4 2016 and held it in 2 quarters. The position peaked at $268K in Q4 2016. 22 funds tracked by Wall St. Rank hold CARM as of Q3 2017.

  • Spark Investment Management reported no remaining Carisma Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Spark Investment Management sold 4,730 Carisma Therapeutics shares in Q3 2017, an estimated $148K.
  • Spark Investment Management first reported a position in Carisma Therapeutics in Q4 2016 and held it in 2 quarters.
  • Spark Investment Management's Carisma Therapeutics position peaked at $268K in Q4 2016.
  • 22 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2017.

Based on Spark Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.